Outlook Therapeutics IncNASDAQ:OTLK
- LAST PRICE1.1400
- TODAY'S CHANGE (%)0.0300 (2.7027%)
- Bid / Lots1.0900/ 6
- Ask / Lots1.1500/ 51
- Open / Previous Close1.1200 / 1.1100
- Day Range
- 52 Week Range
- Volume333,250
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OTLK |
|---|---|---|
| 09:32 ET | 626 | 1.1 |
| 09:33 ET | 100 | 1.1254 |
| 09:35 ET | 600 | 1.115 |
| 09:37 ET | 500 | 1.12 |
| 09:39 ET | 389 | 1.1114 |
| 09:42 ET | 300 | 1.105 |
| 09:44 ET | 230 | 1.105 |
| 09:51 ET | 600 | 1.11 |
| 09:53 ET | 2000 | 1.11 |
| 09:55 ET | 200 | 1.11 |
| 09:57 ET | 3539 | 1.1 |
| 10:00 ET | 700 | 1.1 |
| 10:04 ET | 1200 | 1.1 |
| 10:06 ET | 300 | 1.1 |
| 10:08 ET | 1300 | 1.1 |
| 10:11 ET | 2000 | 1.1 |
| 10:15 ET | 3743 | 1.1 |
| 10:20 ET | 400 | 1.1 |
| 10:22 ET | 19288 | 1.1 |
| 10:24 ET | 750 | 1.1 |
| 10:26 ET | 2500 | 1.1 |
| 10:27 ET | 400 | 1.11 |
| 10:29 ET | 583 | 1.1 |
| 10:31 ET | 200 | 1.1 |
| 10:33 ET | 600 | 1.1 |
| 10:36 ET | 100 | 1.1 |
| 10:38 ET | 800 | 1.1 |
| 10:40 ET | 4778 | 1.1 |
| 10:42 ET | 1952 | 1.095 |
| 10:44 ET | 5800 | 1.1 |
| 10:45 ET | 400 | 1.1 |
| 10:49 ET | 215 | 1.1 |
| 10:51 ET | 300 | 1.1 |
| 10:54 ET | 200 | 1.11 |
| 10:56 ET | 200 | 1.11 |
| 10:58 ET | 200 | 1.11 |
| 11:00 ET | 215 | 1.1 |
| 11:02 ET | 600 | 1.11 |
| 11:03 ET | 300 | 1.105 |
| 11:05 ET | 400 | 1.105 |
| 11:07 ET | 200 | 1.1 |
| 11:09 ET | 300 | 1.1 |
| 11:12 ET | 200 | 1.1 |
| 11:14 ET | 400 | 1.11 |
| 11:16 ET | 600 | 1.1 |
| 11:18 ET | 200 | 1.105 |
| 11:20 ET | 400 | 1.11 |
| 11:21 ET | 500 | 1.1 |
| 11:23 ET | 400 | 1.1 |
| 11:25 ET | 500 | 1.11 |
| 11:27 ET | 100 | 1.1 |
| 11:30 ET | 522 | 1.105 |
| 11:32 ET | 500 | 1.11 |
| 11:34 ET | 300 | 1.105 |
| 11:36 ET | 249 | 1.1 |
| 11:38 ET | 100 | 1.1 |
| 11:41 ET | 100 | 1.1 |
| 11:43 ET | 100 | 1.105 |
| 11:45 ET | 100 | 1.105 |
| 11:48 ET | 100 | 1.1 |
| 11:50 ET | 100 | 1.1 |
| 11:52 ET | 100 | 1.1 |
| 11:56 ET | 100 | 1.1 |
| 12:03 ET | 387 | 1.1 |
| 12:06 ET | 400 | 1.1017 |
| 12:08 ET | 200 | 1.1 |
| 12:10 ET | 300 | 1.1 |
| 12:12 ET | 100 | 1.1 |
| 12:15 ET | 100 | 1.1 |
| 12:19 ET | 645 | 1.1074 |
| 12:21 ET | 700 | 1.105 |
| 12:24 ET | 250 | 1.1001 |
| 12:28 ET | 100 | 1.1 |
| 12:30 ET | 822 | 1.1 |
| 12:33 ET | 100 | 1.1 |
| 12:37 ET | 100 | 1.1 |
| 12:39 ET | 2632 | 1.1 |
| 12:44 ET | 17564 | 1.11 |
| 12:46 ET | 300 | 1.11 |
| 12:48 ET | 100 | 1.11 |
| 12:51 ET | 100 | 1.11 |
| 12:53 ET | 100 | 1.11 |
| 12:55 ET | 200 | 1.11 |
| 12:57 ET | 200 | 1.11 |
| 01:00 ET | 466 | 1.11 |
| 01:02 ET | 100 | 1.11 |
| 01:06 ET | 300 | 1.115 |
| 01:08 ET | 200 | 1.11 |
| 01:09 ET | 100 | 1.111 |
| 01:11 ET | 1500 | 1.11 |
| 01:13 ET | 100 | 1.11 |
| 01:15 ET | 900 | 1.115 |
| 01:20 ET | 100 | 1.11 |
| 01:22 ET | 100 | 1.11 |
| 01:24 ET | 1000 | 1.115 |
| 01:26 ET | 2600 | 1.11 |
| 01:27 ET | 100 | 1.11 |
| 01:29 ET | 1888 | 1.11 |
| 01:31 ET | 200 | 1.11 |
| 01:36 ET | 500 | 1.11 |
| 01:38 ET | 200 | 1.11 |
| 01:40 ET | 100 | 1.11 |
| 01:44 ET | 100 | 1.11 |
| 01:47 ET | 1000 | 1.1128 |
| 01:49 ET | 200 | 1.11 |
| 01:51 ET | 1918 | 1.11 |
| 01:56 ET | 300 | 1.11 |
| 02:00 ET | 4200 | 1.11 |
| 02:02 ET | 100 | 1.1 |
| 02:03 ET | 200 | 1.1 |
| 02:05 ET | 300 | 1.105 |
| 02:07 ET | 18121 | 1.11 |
| 02:14 ET | 1554 | 1.11 |
| 02:16 ET | 200 | 1.1134 |
| 02:21 ET | 1300 | 1.11 |
| 02:23 ET | 100 | 1.1104 |
| 02:25 ET | 822 | 1.11 |
| 02:27 ET | 200 | 1.11 |
| 02:30 ET | 100 | 1.11 |
| 02:32 ET | 100 | 1.11 |
| 02:34 ET | 1477 | 1.11 |
| 02:36 ET | 5400 | 1.115 |
| 02:38 ET | 2800 | 1.12 |
| 02:39 ET | 800 | 1.12 |
| 02:45 ET | 200 | 1.12 |
| 02:52 ET | 300 | 1.12 |
| 02:54 ET | 12447 | 1.12 |
| 02:56 ET | 600 | 1.12 |
| 02:59 ET | 2100 | 1.12 |
| 03:01 ET | 2200 | 1.12 |
| 03:03 ET | 1600 | 1.12 |
| 03:06 ET | 200 | 1.12 |
| 03:10 ET | 1100 | 1.12 |
| 03:12 ET | 1150 | 1.1121 |
| 03:14 ET | 1865 | 1.12 |
| 03:15 ET | 700 | 1.12 |
| 03:17 ET | 2481 | 1.1199 |
| 03:19 ET | 1596 | 1.12 |
| 03:21 ET | 5500 | 1.11 |
| 03:24 ET | 4800 | 1.12 |
| 03:26 ET | 897 | 1.12 |
| 03:28 ET | 1111 | 1.12 |
| 03:32 ET | 1300 | 1.12 |
| 03:33 ET | 3049 | 1.12 |
| 03:35 ET | 200 | 1.125 |
| 03:37 ET | 6985 | 1.12 |
| 03:39 ET | 11774 | 1.115 |
| 03:42 ET | 2281 | 1.12 |
| 03:44 ET | 3400 | 1.12 |
| 03:46 ET | 7083 | 1.12 |
| 03:48 ET | 1800 | 1.12 |
| 03:50 ET | 800 | 1.115 |
| 03:51 ET | 6735 | 1.125 |
| 03:53 ET | 8598 | 1.12 |
| 03:55 ET | 800 | 1.12 |
| 03:57 ET | 3200 | 1.12 |
| 04:00 ET | 66421 | 1.14 |
Jan 19, 2023
BRIEF-Outlook Therapeutics® Strengthens Medical Affairs And Commercial Expertise With Appointments Of Surendra Sharma, MD, Senior Vice President Of Medical Affairs And Glen Olsheim, Executive Director Of Commercial Excellence, from 9:00AM ET on Thursday Jan 19, 2023 by Thomson Reuters
9:00AM ET on Thursday Jan 19, 2023 by Thomson ReutersOutlook Therapeutics(R) Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence, from 8:05AM ET on Thursday Jan 19, 2023 by GlobeNewswire
8:05AM ET on Thursday Jan 19, 2023 by GlobeNewswire
Jan 11, 2023
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th, from 1:05PM ET on Wednesday Jan 11, 2023 by Accesswire
1:05PM ET on Wednesday Jan 11, 2023 by Accesswire
Jan 9, 2023
Outlook Therapeutics(R) to Present at the Virtual Investor 2023 Companies to Watch Event, from 8:05AM ET on Monday Jan 09, 2023 by GlobeNewswire
8:05AM ET on Monday Jan 09, 2023 by GlobeNewswire
Jan 6, 2023
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating, from 9:39AM ET on Friday Jan 06, 2023 by MT Newswires
9:39AM ET on Friday Jan 06, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Outlook Therapeutics Inc | 284.9M | -3.7x | --- |
Rallybio Corp | 285.6M | -3.7x | --- |
LianBio | 287.1M | -2.4x | --- |
Actinium Pharmaceuticals Inc | 284.6M | -8.8x | --- |
PDS Biotechnology Corp | 277.9M | -9.2x | --- |
Savara Inc | 292.0M | -10.0x | --- |
Company Information
Outlook Therapeutics, Inc. (Outlook) is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
Contact Information
- Headquarters
- 485 Route 1 South, Building F, Suite 320ISELIN, NJ, United States 08830
- Phone
- 609-619-3990
- Fax
- ---
Executives
- Director
- Ralph Thurman
- President, Chief Executive Officer, Director
- C. Russell Trenary
- Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
- Lawrence Kenyon
- Chief Operations Officer
- Terry Dagnon
- Senior Vice President - Marketing & Market Access
- Alicia Tozier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $284.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 256.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-0.31 |
Book Value | $0.04 |
P/E Ratio | -3.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
